Navigation Links
For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients
Date:12/8/2010

BURLINGTON, Mass., Dec. 8, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

The Pharmacor 2010 findings from the topic entitled Ovarian Cancer which will publish later this month reveal that, since the publication of data last year from the CALYPSO clinical trial, PLD (Centocor Ortho Biotech/Janssen's Doxil, Merck's Caelyx) is being increasingly used in combination with carboplatin (Bristol-Myers Squibb's Paraplatin, generics) as an alternative to paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin in the second-line, platinum-sensitive population. As a result, Decision Resources forecasts that PLD/carboplatin will replace paclitaxel/carboplatin by 2019 as the gold-standard treatment in this setting in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

According to the findings, urgent unmet need remains for therapies that can delay or prevent progression to platinum-resistant ovarian cancer.

"Experts we interviewed believe that such gains in addressing unmet need will most likely come from novel targeted agents," said Decision Resources Analyst Niamh Murphy, Ph.D. "As such, the need exists to identify other genetic characteristics -- in addition to BRCA1/BRCA2 mutations -- that will lead to the development of novel, molecularly targeted drugs which will benefit patients with ovarian cancer."

The findings also reveal that dramatic growth in the ovarian cancer drug market through 2019 will be driven primarily by the approval and uptake of four premium priced targeted ther
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Tobramycin ... Tobramycin is a traditional antibiotic whose eye drop and ... treatment of potential infection or inflammation caused by eye ... are able to produce tobramycin, among which ...
(Date:8/28/2015)... , Aug. 28, 2015 Patterson Medical, ... (Nasdaq: PDCO ), is now an independent ... acquisition of Patterson Medical by Madison Dearborn Partners ... its name for a transition period before rebranding ... and sports medicine products.  With the focused resources ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... to their offering. Developed by Novo ... Novolog) is an important drug for the treatment ... as a fast- acting insulin analog, starts working ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... , MT. LAUREL, N.J., Dec. 1 ... of technology-enabled clinical documentation services, today announced that the radiology ... SpeechQ for Radiology(TM), MedQuist,s real-time speech recognition system. The solution ... (RSNA) convention November 29 through December 2. ...
... , PISCATAWAY, N.J., Dec. 1 Siemens ... hearing instruments, announced its third annual partnership with Quota International,s ... 2010. , As part of the renewed partnership, Siemens is ... instruments to both children and young adults, age 23 years ...
Cached Medicine Technology:MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3
(Date:8/28/2015)... Columbus, Ohio (PRWEB) , ... August 28, 2015 ... ... Saturday’s Imagine No Malaria Day at the Zoo to celebrate children helping children, ... people and their congregations throughout West Ohio have contributed to the United Methodist ...
(Date:8/28/2015)... ... , ... For Dallas, the time is nearing for the annual Heart Walk, ... , The American Heart Association hosts their well-known Heart Walk to raise money in ... difference can be made. Walkers can participate in the cause and someone can also ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, ... the “Music With A Mission” benefit concert in Mendon, IL. Held in the Show ... money to support music education programs in the underfunded local school districts of Mendon ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... documenting and diagramming network and data center assets and audio-video devices, recently released ... Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series , Super Micro ...
(Date:8/28/2015)... Utah (PRWEB) , ... August 28, 2015 , ... ... awarded a three-year accreditation for its adolescent residential, counseling, day treatment and intensive ... that it meets international standards for quality and its pursuit of excellence. As ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... for tuberculosis has revealed that nearly 40% of the doctors ... levels// in those who work in TB clinics. The research ... is a growing problem worldwide. Russia is one country where ... the world's population are infected with the bacterium that causes ...
... breast cancer therapy drug tamoxifen, to another one exemestane//, could ... their findings in the online version of The Lancet, researchers ... and team, stood for changing treatments tracks to exemestane after ... reduced deaths by 17 percent. ,Their findings stem ...
... drug that aids patients who suffer from persistent iron overload ... ,Patients suffering from a rare genetic condition or ... transfusions. Generally these people are given a painful infusion at ... hours. ,But the new drug Exjade is an ...
... Carnegie Institution's Department of Plant Biology have discovered ... regulation—neighboring pore-like structures at the cell's surface physically ... nutrient, nitrogen. It is the first time scientists ... is essential to this regulation. Since plants, animals, ...
... new technique that uses ozone to preserve grapes could help ... reports Jennifer Rohn in Chemistry & Industry, the magazine of ... wine-making process to produce healthier wines without the added sulphites ... ,Mass-marketed grapes can remain in storage for months ...
... research currently underway brings hope of dramatic advances ... review//. The review reveals that new approaches in ... chemotherapy, and research on breast cancer vaccines may ... physician treating breast cancer patients. These new tools ...
Cached Medicine News:Health News:New Drug Therapy for Breast Cancer Offers Hope 2Health News:New Mechanism for Nutrient Uptake Discovered 2Health News:New Mechanism for Nutrient Uptake Discovered 3Health News:Grape Expectations for Healthier Wine 2Health News:Emerging Research Heralds New Era of Breast Cancer Management 2
Welch Allyn introduced halogen HPX lamp technology to provide 30% more light output than previous halogen lamps. The mix of halogen and xenon gases provide whiter, longer lasting light - making your ...
RT-600 Refractor...
... Ultramatic Rx Master is designed ... of reliable service and give ... measurably improve procedures. It embodies ... and want most, including accuracy, ...
Occluder and Maddox Rod...
Medicine Products: